DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) today announced the Company is scheduled to present at the Bank of America Consumer and Retail Technology Conference 2021 on Tuesday, March 9, 2021 at 2:30 p.m. Eastern Time. A …
Category: Business
Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System
LOS ANGELES–(BUSINESS WIRE)–Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. Foo…
Refac Holdings Announces Acquisition by Lincoln Road Advisors
BLACKWOOD, N.J.–(BUSINESS WIRE)–Refac Holdings, Inc. announces the completion of its acquisition by Lincoln Road Advisors, Inc.
Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of the Company’s Investigational Treatment for Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics today announced topline results from a phase 2a program evaluating the company’s investigational therapy for the treatment of MGD.
Beverly Capital Invests in The Eye Health Group
LOS ANGELES–(BUSINESS WIRE)–Beverly Capital, a Los Angeles-based private equity firm, announced today that it has acquired The Eye Health Group, a New Jersey-based medical optometric service provider. The Eye Health Group is a leading vision support …
Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2020 and provided a general business update.
National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2020 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the fourth quarter and fiscal year ended January 2, 2021 and is providing its outlook for fiscal 20…
Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board
RESEARCH TRIANGLE PARK, N.C. & MALMÖ, Sweden–(BUSINESS WIRE)–Craig is the former Head of Clinical Innovation and Venture Partner at Pfizer
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the a…
Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report i…
Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer
LONDON–(BUSINESS WIRE)–Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer.
Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that Glenn Sblendorio, CEO, and Pravin Dugel, CSO, CBO, will participate in a fireside chat at the Cowen Conference on March 4.
Takeda Fornece Atualizações sobre Testes Clínicos da Fase 1/2 de Candidatos à Vacina para COVID-19 da Novavax e Moderna no Japão
OSAKA, Japão–(BUSINESS WIRE)–A Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunciou hoje que o primeiro indivíduo foi dosado na fase 1/2 do estudo de imunogenicidade e segurança da vacina candidata para COVID-19 da Novavax (TAK-019) no …
Takeda proporciona información actualizada sobre los ensayos clínicos de fase 1/2 de las candidatas a vacunas contra la COVID-19 de Novavax y Moderna en Japón
OSAKA, Japón–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ha anunciado hoy la administración de la primera dosis en su estudio de inmunogenicidad y seguridad de fase 1/2 de la vacuna candidata contra la COVID-19 de Novava…
Takeda présente des mises à jour sur les essais cliniques de Phase 1/2 portant sur les candidats vaccins contre la COVID-19 de Novavax et Moderna au Japon
OSAKA, Japon–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) annonce aujourd’hui le dosage du premier patient dans son étude de Phase 1/2 portant sur l’immunogénicité et l’innocuité du vaccin candidat contre la COVID-19 de N…
Takeda informiert über den aktuellen Stand der klinischen Phase 1/2-Studien mit den COVID-19-Impfstoffkandidaten von Novavax und Moderna in Japan
OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) gab heute bekannt, dass der erste Proband im Rahmen der Phase-1/2-Studie zu Sicherheit und Immunogenität des COVID-19-Impfstoffkandidaten (TAK-019) von Novavax in …
Riassunto: Takeda fornisce aggiornamenti sugli studi clinici di fase 1/2 dei candidati vaccini anti COVID-19 di Novavax e Moderna in Giappone
OSAKA, Giappone–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato l’inoculazione del primo soggetto dello studio di fase 1/2 su immunogenicità e sicurezza del candidato vaccino anti COVID-19 di Novavax (TAK-…